RLT Patient Referral Pathways for Prostate Cancer (Mar. 2026)

Consensus Project on Optimising RLT Patient Referral Pathways for Prostate Cancer

EANM is pleased to highlight the launch of the Consensus Project on Optimising RLT Patient Referral Pathways for Prostate Cancer.

The initiative brings together six leading European medical societies—EANM, the European Association of Urology (EAU), the European Society for Medical Oncology (ESMO), European Society for Radiotherapy and Oncology (ESTRO), and the European Society of Radiology (ESR)—alongside patient advocates from Europa Uomo. This unprecedented multidisciplinary collaboration, led by EANM, aims to define harmonised, efficient, and equitable referral pathways for Radioligand Therapy (RLT), an emerging precision oncology approach that combines molecular diagnostics with targeted treatment.

While RLT is now an established option for advanced prostate cancer, clinical pathways across Europe have yet to fully adapt. This gap impacts equitable access, resource allocation, and patient outcomes. In response to the EU Cancer Mission’s call for implementation-oriented action, the project focuses not on clinical efficacy, but on improving system-level coordination and referral processes.

EANM sincerely thanks the leadership of all participating scientific societies and patient advocacy groups for their commitment and invaluable contributions to this collaborative effort. Their dedication is key to advancing more integrated, equitable, and patient-centered prostate cancer care across Europe.

More information about the outcomes of the project will be shared in the coming months. For further information, please contact EANM Strategy Implementation Director Silvia Marchetti at s.marchetti@eanm.org.

Published online: March 24, 2026.